JMP Securities analyst Reni Benjamin has maintained their neutral stance on ACET stock, giving a Hold rating on February 27.
Reni Benjamin has given his Hold rating due to a combination of factors, primarily focusing on the current valuation and upcoming clinical data. Adicet Bio’s shares are considered fairly valued, trading at a discount that aligns with other biotech firms facing similar uncertainties. The company’s solid cash position of $176.3 million supports this valuation, but the lack of revenue and the need for key clinical data updates contribute to the cautious stance.
The anticipated data readouts from Phase 1 trials in LN and RCC in the first half of 2025 are crucial for determining the potential of Adicet’s engineered gamma-delta T cells as a superior therapeutic option. Until these results are available, the stock remains a hold as the outcomes could significantly influence the company’s future prospects and valuation.
According to TipRanks, Benjamin is an analyst with an average return of -15.1% and a 29.61% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, BeiGene, and Incyte.
Questions or Comments about the article? Write to editor@tipranks.com